Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5979280 | 0.94 | — | — | |
| SCHEMBL5344482 | 0.94 | — | — | |
| SCHEMBL5399496 | 0.81 | MEN1 (0.34) | MEN1KMT2AEPHX2CCNA2CDK2 | |
| SCHEMBL9354384 | 0.81 | MEN1 (0.41) | MEN1KMT2AEPHX2SLC6A3LMNA | |
| SCHEMBL7716652 | 0.81 | MEN1 (0.41) | MEN1KMT2AEPHX2SLC6A3LMNA | |
| SCHEMBL28647211 | 0.81 | MEN1 (0.38) | MEN1KMT2AEPHX2SLC6A3SMN1; SMN2 | |
| SCHEMBL6554397 | 0.81 | MEN1 (0.38) | MEN1KMT2AEPHX2SLC6A3LMNA | |
| SCHEMBL12118788 | 0.79 | TSHR (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL567667 | 0.79 | TSHR (0.40) | MEN1KMT2ASLC6A3 | |
| SCHEMBL64929 | 0.79 | MEN1 (0.37) | MEN1KMT2AEPHX2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3959213-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0521496-B1 | Process for producing optically active carboxylic acids | CONSORTIUM ELEKTROCHEM IND (DE) | 1994-10-19 | — | — | EP | disclosed |
| EP-0521496-A2 | Process for producing optically active carboxylic acids | Consortium für elektrochemische Industrie GmbH (DE) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | JAK1, JAK3, JAK2 | MEN1 4376/4885KMT2A 1395/4885EPHX2 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.